UNSPSC 51263007: Dapiprazole hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DS9UJN1I0X, chemically known as 5,6,7,8-tetrahydro-3-(2-(4-o-tolyl-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine monohydrochloride but more generally known as dapiprazole hydrochloride, which bears US NIH Compound Identifier 91269. European Medicines Agency schedules Dapiprazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01554MIG.

UNSPSC 51263007 Dapiprazole hydrochloride is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though the recent opportunities tagged under it reflect broader pharmaceutical and pharmacy benefit sourcing rather than dapiprazole specifically. State and local governments use this code tier to solicit individual pharmaceutical products and related drug-distribution services. The issuing bodies include county health departments and state health agencies; Seminole County, Florida and the Texas Health and Human Services Commission represent the mix of municipal and state-level buyers active under this code recently.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building (response deadline July 26, 2023, now closed), while the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Geographic activity appears concentrated in the South, with Florida and Texas representing recent solicitation activity; the Texas inquiry suggests broader state-level interest in pharmacy benefit restructuring beyond individual pharmaceutical procurement.